BEAM241220P40000
- 16.63
- 0.000.00%
Beam Therapeutics Newsroom
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Beam Therapeutics Is Maintained at Sector Perform by RBC Capital
Scotiabank Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Cuts Target Price to $24
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $31 to $69
Beam Therapeutics Analyst Ratings
JonesTrading Sticks to Their Hold Rating for Beam Therapeutics (BEAM)
Buy Rating Affirmed for Beam Therapeutics Due to Promising BEAM-101 Developments in Sickle Cell Disease Treatment
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Beam Therapeutics Price Target Announced at $24.00/Share by Scotiabank
Beam Therapeutics Analyst Ratings
Beam Therapeutics Initiated With a Sector Perform at Scotiabank
RBC Capital Maintains Beam Therapeutics(BEAM.US) With Hold Rating, Maintains Target Price $27
JonesTrading Initiates Beam Therapeutics(BEAM.US) With Hold Rating
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Raises Target Price to $69
Stifel Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Cuts Target Price to $69
Beam Therapeutics Is Maintained at Buy by Stifel
Beam Therapeutics Analyst Ratings
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)
Beam Therapeutics: Hold Rating With Stable Financial Outlook Amid Clinical Pipeline Progress and Upcoming Data Releases